LifeStance Reports Second Quarter 2022 Results
LifeStance Health Group, Inc. (NASDAQ: LFST) reported Q2 2022 revenue of $209.5 million, a 31% increase from the previous year. The total clinician count rose to 5,226, with a net gain of 237 in the quarter. Despite a net loss of $68.7 million, a slight improvement from the prior year's loss, adjusted EBITDA remained steady at $14.6 million. The company expects full-year revenue and center margin towards the lower end of previous guidance due to changes in clinician availability. Full-year adjusted EBITDA guidance was reaffirmed at $63 million to $67 million.
- Revenue increased by 31% to $209.5 million compared to Q2 2021.
- Total clinicians rose to 5,226, a net addition of 237 in the quarter.
- Adjusted EBITDA remained stable at $14.6 million, reflecting operational efficiency.
- Net loss was $68.7 million, slightly improved from last year's $70.0 million loss.
- Loss from operations increased to $60.5 million, impacted by $57.5 million stock-based compensation.
- Revenue expectations for the full year were lowered due to clinician time off, indicating potential operational challenges.
SCOTTSDALE, Ariz., Aug. 09, 2022 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, today announced financial results for the quarter ended June 30, 2022.
(All results compared to prior-year comparative period, unless otherwise noted)
Q2 2022 Highlights and FY 2022 Outlook
- Revenue of
$209.5 million increased$49.0 million or31% compared to revenue of$160.5 million - Total clinicians of 5,226 up
31% , a net increase of 237 in the second quarter - Net loss of
$68.7 million compared to net loss of$70.0 million , primarily driven by stock-based compensation expense of$57.5 million - Adjusted EBITDA of positive
$14.6 million compared to Adjusted EBITDA of positive$14.5 million - Expecting full year 2022 revenue and Center Margin toward the bottom end of the previously guided ranges of
$865 million to$885 million and$240 million to$255 million , respectively, due to refined clinician seasonality assumptions; reaffirming Adjusted EBITDA guidance of$63 million to$67 million
"We delivered another quarter of solid results,” said Michael Lester, Chairman and CEO of LifeStance. “This quarter was highlighted by profitability performance that was consistent with our expectations. We are proud of the critical role we play in helping patients navigate their mental health journey while demonstrating the effectiveness of our unique hybrid business model, which is focused on meeting patient needs through innovations that make mental health care more affordable and accessible."
| Financial Highlights | ||||||||||||
| Q2 2022 | Q2 2021 | Y/Y | ||||||||||
| (in millions) | ||||||||||||
| Total revenue | $ | 209.5 | $ | 160.5 | 31 | % | ||||||
| Loss from operations | (60.5 | ) | (47.0 | ) | 29 | % | ||||||
| Center Margin | 59.8 | 51.2 | 17 | % | ||||||||
| Net loss | (68.7 | ) | (70.0 | ) | (2 | %) | ||||||
| Adjusted EBITDA | 14.6 | 14.5 | 1 | % | ||||||||
| As % of Total revenue: | ||||||||||||
| Loss from operations | (28.9 | %) | (29.3 | %) | ||||||||
| Center Margin | 28.5 | % | 31.9 | % | ||||||||
| Net loss | (32.8 | %) | (43.6 | %) | ||||||||
| Adjusted EBITDA | 7.0 | % | 9.1 | % | ||||||||
(All results compared to prior-year period, unless otherwise noted)
- Revenue grew
31% to$209.5 million . Strong revenue growth was supported by a31% net increase in total clinicians, driven by hiring and acquisitions. Second quarter revenue performance was impacted by approximately$4 million of incremental clinician time off in June relative to expectations. - Loss from operations of
$60.5 million , primarily driven by stock-based compensation expense of$57.5 million . Net loss of$68.7 million . - Center Margin grew
17% to$59.8 million , or28.5% of revenue. Center Margin as a percentage of revenue declined as new clinicians ramp to maturity. - Adjusted EBITDA remained relatively flat at
$14.6 million , or7.0% of revenue. Adjusted EBITDA as a percentage of revenue declined due to the decrease in Center Margin as a percentage of revenue, partially offset by improved leverage in operating expenses.
Strategy and Key Developments
During the second quarter, LifeStance took several actions to support the company’s strategy to expand into new markets, build market density and offer a technology-enabled experience for patients and clinicians, including:
- Drove
31% year-over-year growth to 5,226 clinicians with the addition of 237 net clinicians in the quarter, demonstrating that the company’s value proposition continues to resonate in the market - Completed four acquisitions, bringing the total since inception to 83
- Opened 27 de novo centers to support the company's differentiated hybrid model offering both in-person and virtual care
- Continued to deploy proprietary online booking and intake experience ("OBIE") across the country, which is now live in nine states
- Danish Qureshi named Chief Operating Officer, effective July 1, 2022; Qureshi is a co-founder and previously served as Chief Growth Officer at LifeStance, overseeing all growth initiatives for the company including clinician recruiting, de novo center openings, payor contracting, customer care and national marketing
- Gwen Booth named Executive Director of LifeStance Health Foundation following her retirement as Chief Operating Officer at LifeStance; Booth will lead the Foundation's work to improve mental health access for especially vulnerable patients including youth and adolescents, underrepresented minority communities and the underemployed and uninsured
Balance Sheet, Cash Flow and Capital Allocation
For the six months ended June 30, 2022, LifeStance provided
2022 Guidance1
LifeStance now expects full year 2022 revenue and Center Margin toward the bottom end of the previously guided ranges of
LifeStance is reaffirming full year 2022 Adjusted EBITDA guidance of
For the third quarter of 2022, the company expects revenue of
“For the full year, we are lowering our revenue expectations slightly based on refinement of our clinician seasonality assumptions,” said Lester. “We continue to focus our planned investments to grow and optimize our clinician base while continuing to drive leverage in our operating costs.”
Footnotes:
(1) Guidance for the third quarter of 2022 and full year 2022 assumes no further COVID-related impacts or changes in the labor market environment.
Conference Call, Webcast Information, and Presentation
LifeStance will hold a conference call today, August 9, at 4:30 p.m. Eastern Time to discuss second quarter 2022 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 3842667 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.
About LifeStance Health Group, Inc.
Founded in 2017, LifeStance (NASDAQ: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance employs approximately 5,200 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 32 states and approximately 600 centers. To learn more, please visit www.LifeStance.com.
We routinely post information that may be important to investors on the “Investor Relations” section of our website at investor.lifestance.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Forward-Looking Statements
Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. These statements include, but are not limited to full-year and third-quarter guidance and management’s related assumptions, statements about the company’s financial position; business plans and objectives; general economic and industry trends; operating results; and working capital and liquidity and other statements contained in this presentation that are not historical facts. When used in this press release and on the related teleconference, words such as “may,” “will,” “should,” “could,” “intend,” “potential,” “continue,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “target,” “predict,” “project,” “seek” and similar expressions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with affiliated practices, which we do not own, to provide health care services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business, results of operations and financial condition would be harmed; the impact of health care reform legislation and other changes in the healthcare industry and in health care spending on us is currently unknown, but may harm our business; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; actual or anticipated changes or fluctuations in our results of operations; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2021. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.
Non-GAAP Financial Information
This press release contains certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA margin. Tables showing the reconciliation of these non-GAAP financial measures to the comparable GAAP measures are included at the end of this release. Management believes these non-GAAP financial measures are useful in evaluating the company’s operating performance, and may be helpful to securities analysts, institutional investors and other interested parties in understanding the company’s operating performance and prospects. These non-GAAP financial measures, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. Therefore, the company’s non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net loss or loss from operations.
Center Margin and Adjusted EBITDA anticipated for the third quarter of 2022 and full year 2022 are calculated in a manner consistent with the historical presentation of these measures at the end of this release. Reconciliation for the forward-looking third quarter of 2022 and full year 2022 Center Margin and Adjusted EBITDA guidance is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. As such, LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.
Management acknowledges that there are many items that impact a company’s reported results and the adjustments reflected in these non-GAAP measures are not intended to present all items that may have impacted these results.
Consolidated Financial Information and Reconciliations
CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands, except for par value)
| June 30, 2022 | December 31, 2021 | |||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 96,686 | $ | 148,029 | ||||
| Patient accounts receivable, net | 99,740 | 76,078 | ||||||
| Prepaid expenses and other current assets | 47,860 | 42,413 | ||||||
| Total current assets | 244,286 | 266,520 | ||||||
| NONCURRENT ASSETS | ||||||||
| Property and equipment, net | 190,694 | 152,242 | ||||||
| Intangible assets, net | 282,088 | 300,355 | ||||||
| Goodwill | 1,243,721 | 1,204,544 | ||||||
| Other noncurrent assets | 7,888 | 3,448 | ||||||
| Total noncurrent assets | 1,724,391 | 1,660,589 | ||||||
| Total assets | $ | 1,968,677 | $ | 1,927,109 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable | $ | 12,941 | $ | 14,152 | ||||
| Accrued payroll expenses | 61,215 | 60,002 | ||||||
| Other accrued expenses | 26,209 | 26,510 | ||||||
| Current portion of contingent consideration | 8,984 | 14,123 | ||||||
| Other current liabilities | 2,191 | 1,965 | ||||||
| Total current liabilities | 111,540 | 116,752 | ||||||
| NONCURRENT LIABILITIES | ||||||||
| Long-term debt, net | 203,364 | 157,416 | ||||||
| Other noncurrent liabilities | 64,538 | 50,325 | ||||||
| Contingent consideration, net of current portion | 3,653 | 3,307 | ||||||
| Deferred tax liability, net | 54,281 | 54,281 | ||||||
| Total noncurrent liabilities | 325,836 | 265,329 | ||||||
| Total liabilities | $ | 437,376 | $ | 382,081 | ||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Preferred stock – par value | — | — | ||||||
| Common stock – par value | 3,763 | 3,743 | ||||||
| Additional paid-in capital | 2,015,665 | 1,898,357 | ||||||
| Accumulated deficit | (488,127 | ) | (357,072 | ) | ||||
| Total stockholders' equity | 1,531,301 | 1,545,028 | ||||||
| Total liabilities and stockholders’ equity | $ | 1,968,677 | $ | 1,927,109 | ||||
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(In thousands, except for Net Loss per Share)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| TOTAL REVENUE | $ | 209,527 | $ | 160,549 | $ | 412,622 | $ | 303,681 | ||||||||
| OPERATING EXPENSES | ||||||||||||||||
| Center costs, excluding depreciation and amortization shown separately below | 149,697 | 109,341 | 298,590 | 208,475 | ||||||||||||
| General and administrative expenses | 103,559 | 85,479 | 206,928 | 118,130 | ||||||||||||
| Depreciation and amortization | 16,743 | 12,774 | 32,427 | 25,002 | ||||||||||||
| Total operating expenses | $ | 269,999 | $ | 207,594 | $ | 537,945 | $ | 351,607 | ||||||||
| LOSS FROM OPERATIONS | $ | (60,472 | ) | $ | (47,045 | ) | $ | (125,323 | ) | $ | (47,926 | ) | ||||
| OTHER EXPENSE | ||||||||||||||||
| Loss on remeasurement of contingent consideration | (180 | ) | (250 | ) | (614 | ) | (557 | ) | ||||||||
| Transaction costs | (19 | ) | (1,996 | ) | (297 | ) | (3,530 | ) | ||||||||
| Interest expense | (7,133 | ) | (23,174 | ) | (10,574 | ) | (31,806 | ) | ||||||||
| Other expense | — | (1,356 | ) | — | (1,445 | ) | ||||||||||
| Total other expense | $ | (7,332 | ) | $ | (26,776 | ) | $ | (11,485 | ) | $ | (37,338 | ) | ||||
| LOSS BEFORE INCOME TAXES | (67,804 | ) | (73,821 | ) | (136,808 | ) | (85,264 | ) | ||||||||
| INCOME TAX (PROVISION) BENEFIT | (923 | ) | 3,788 | 5,753 | 6,549 | |||||||||||
| NET LOSS | $ | (68,727 | ) | $ | (70,033 | ) | $ | (131,055 | ) | $ | (78,715 | ) | ||||
| Accretion of Redeemable Class A units | — | — | — | (36,750 | ) | |||||||||||
| NET LOSS AVAILABLE TO COMMON STOCKHOLDERS/MEMBERS | $ | (68,727 | ) | $ | (70,033 | ) | $ | (131,055 | ) | $ | (115,465 | ) | ||||
| NET LOSS PER SHARE, BASIC AND DILUTED | (0.19 | ) | (0.22 | ) | (0.37 | ) | (0.37 | ) | ||||||||
| Weighted-average shares used to compute basic and diluted net loss per share | 353,729 | 313,536 | 352,297 | 309,559 | ||||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(In thousands)
| Six Months Ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net loss | $ | (131,055 | ) | $ | (78,715 | ) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization | 32,427 | 25,002 | ||||||
| Stock and unit-based compensation | 117,365 | 30,120 | ||||||
| Loss on debt extinguishment | 3,380 | 5,620 | ||||||
| Amortization of discount and debt issue costs | 748 | 1,081 | ||||||
| Loss on remeasurement of contingent consideration | 614 | 557 | ||||||
| Endowment of shares to LifeStance Health Foundation | — | 9,000 | ||||||
| Change in operating assets and liabilities, net of businesses acquired: | ||||||||
| Patient accounts receivable, net | (21,900 | ) | (11,831 | ) | ||||
| Prepaid expenses and other current assets | (5,351 | ) | (14,964 | ) | ||||
| Accounts payable | 1,731 | 2,261 | ||||||
| Accrued payroll expenses | (289 | ) | 9,580 | |||||
| Other accrued expenses | 13,471 | 15,283 | ||||||
| Net cash provided by (used in) operating activities | 11,141 | (7,006 | ) | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Purchases of property and equipment | (53,775 | ) | (31,803 | ) | ||||
| Acquisitions of businesses, net of cash acquired | (35,118 | ) | (39,126 | ) | ||||
| Net cash used in investing activities | (88,893 | ) | (70,929 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Proceeds from initial public offering, net of underwriters discounts and commissions and deferred offering costs | — | 554,169 | ||||||
| Issuance of common units to new investors | — | 1,000 | ||||||
| Proceeds from long-term debt, net of discount | 228,000 | 98,800 | ||||||
| Payments of debt issue costs | (7,184 | ) | (2,360 | ) | ||||
| Payments of long-term debt | (181,230 | ) | (310,729 | ) | ||||
| Prepayment for debt paydown | (1,609 | ) | — | |||||
| Payments of contingent consideration | (11,090 | ) | (5,587 | ) | ||||
| Taxes related to net share settlement of equity awards | (478 | ) | — | |||||
| Net cash provided by financing activities | 26,409 | 335,293 | ||||||
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | (51,343 | ) | 257,358 | |||||
| Cash and Cash Equivalents - Beginning of period | 148,029 | 18,829 | ||||||
| CASH AND CASH EQUIVALENTS – END OF PERIOD | $ | 96,686 | $ | 276,187 | ||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||||||||
| Cash paid for interest | $ | 4,927 | $ | 24,889 | ||||
| Cash paid for taxes, net of refunds | $ | 860 | $ | 900 | ||||
| SUPPLEMENTAL DISCLOSURES OF NON CASH INVESTING AND FINANCING ACTIVITIES | ||||||||
| Unpaid deferred offering costs included in accounts payable and other accrued expenses | $ | — | $ | 5,264 | ||||
| Equipment financed through capital leases | $ | 256 | $ | 14 | ||||
| Contingent consideration incurred in acquisitions of businesses | $ | 5,683 | $ | 2,739 | ||||
| Acquisition of property and equipment included in liabilities | $ | 13,055 | $ | 10,233 | ||||
| Issuance of common units for acquisitions of businesses | $ | — | $ | 1,486 | ||||
RECONCILIATION OF LOSS FROM OPERATIONS TO CENTER MARGIN
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands) | ||||||||||||||||
| Loss from operations | $ | (60,472 | ) | $ | (47,045 | ) | $ | (125,323 | ) | $ | (47,926 | ) | ||||
| Adjusted for: | ||||||||||||||||
| Depreciation and amortization | 16,743 | 12,774 | 32,427 | 25,002 | ||||||||||||
| General and administrative expenses(1) | 103,559 | 85,479 | 206,928 | 118,130 | ||||||||||||
| Center Margin | $ | 59,830 | $ | 51,208 | $ | 114,032 | $ | 95,206 | ||||||||
(1) Represents salaries, wages and employee benefits for our executive leadership, finance, human resources, marketing, billing and credentialing support and technology infrastructure and stock and unit-based compensation for all employees.
RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA
(unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (in thousands) | ||||||||||||||||
| Net loss | $ | (68,727 | ) | $ | (70,033 | ) | $ | (131,055 | ) | $ | (78,715 | ) | ||||
| Adjusted for: | ||||||||||||||||
| Interest expense | 7,133 | 23,174 | 10,574 | 31,806 | ||||||||||||
| Depreciation and amortization | 16,743 | 12,774 | 32,427 | 25,002 | ||||||||||||
| Income tax provision (benefit) | 923 | (3,788 | ) | (5,753 | ) | (6,549 | ) | |||||||||
| Loss on remeasurement of contingent consideration | 180 | 250 | 614 | 557 | ||||||||||||
| Stock and unit-based compensation expense | 57,510 | 29,515 | 117,365 | 30,120 | ||||||||||||
| Management fees(1) | — | 1,356 | — | 1,445 | ||||||||||||
| Transaction costs(2) | 19 | 1,996 | 297 | 3,530 | ||||||||||||
| Offering related costs(3) | — | 8,747 | — | 8,747 | ||||||||||||
| Endowment to the LifeStance Health Foundation | — | 10,000 | — | 10,000 | ||||||||||||
| Other expenses(4) | 851 | 544 | 2,645 | 1,176 | ||||||||||||
| Adjusted EBITDA | $ | 14,632 | $ | 14,535 | $ | 27,114 | $ | 27,119 | ||||||||
(1) Represents management fees paid to certain of our executive officers and affiliates of our Principal Stockholders pursuant to the management services agreement entered into in connection with the TPG Acquisition. The management services agreement terminated in connection with the IPO.
(2) Primarily includes capital markets advisory, consulting, accounting and legal expenses related to our acquisitions.
(3) Primarily includes non-recurring incremental professional services, such as accounting and legal, and directors' and officers' insurance incurred in connection with the IPO.
(4) Primarily includes costs incurred to consummate or integrate acquired centers, certain of which are wholly-owned and certain of which are affiliated practices, in addition to the fees paid to former owners of acquired centers and related expenses that are not reflective of the ongoing operating expenses of our centers. Acquired center integration and other are components of general and administrative expenses included in our unaudited consolidated statements of operations. Former owner fees is a component of center costs, excluding depreciation and amortization included in our unaudited consolidated statements of operations.
FAQ
What are LifeStance's Q2 2022 revenue results?
How did LifeStance's clinician count change in Q2 2022?
What was LifeStance's adjusted EBITDA in Q2 2022?
What is LifeStance's outlook for full-year 2022 revenue?
How did LifeStance's net loss in Q2 2022 compare to the previous year?
